AFFILIATIONS
1 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
2 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Clinical Laboratory, People's Hospital Affiliated to Fujian Traditional Chinese Medicine University, Fujian, Fuzhou, China, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
3 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States, The First People Hospital of Foshan, School of Medicine, Southern University of science and Technology, Foshan, Guangdong, China
4 Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, United States
5 Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, California, United States
6 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
7 Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, United States
8 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
9 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
10 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
11 Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
12 Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) activity are mediated by the same alloreactive T cells and preventing GVHD while preserving GVL activity remains an elusive goal for allogeneic hematopoietic cell transplantation (Allo-HCT). Polyamines support T cell proliferation and metabolic fitness, but whether polyamine metabolism can be targeted to separate GVL activity from GVHD remains unclear. Ornithine decarboxylase 1 (ODC1) is critical for endogenous polyamine synthesis and can be inhibited with difluoromethylornithine (DFMO). DFMO was reported to attenuate acute GVHD ~3 decades ago, although mechanisms remained unclear (PMID: 1451328). We first tested whether disruption of endogenous polyamine synthesis by ODC1 knockout in donor T cells was sufficient to prevent GVHD. However, ODC1-deficient donor T cells induced lethal acute GVHD comparable to that induced by wild-type donor T cells, indicating that ODC1 deficiency alone was insufficient to prevent GVHD. This residual pathogenicity was associated with a surge in serum polyamines that peaked on day 7 after HCT. We therefore hypothesized that uptake of exogenous polyamines compensates for defective endogenous polyamine synthesis and allows ODC1-deficient donor T cells to retain GVHD pathogenicity.
We tested this hypothesis by combining donor T-cell ODC1 deficiency with transient blockade of exogenous polyamine uptake by AMXT-1501 treatment. Addition of three daily (days 3-5) peritoneal injections of AMXT-1501 effectively prevented acute GVHD while preserving strong GVL activity that eliminated ALL cells, with 100% recipients survived for more than 60 days while controls all died of GVHD and/or tumor growth by ~15 days after HCT. We next investigated how dual polyamine blockade selectively suppressed GVHD-mediating donor T cells while preserving GVL function. Mechanistic analysis with combined scRNA-Seq with TCR-CDR3-Seq, Western blot, flow cytometry, and Seahorse demonstrated that, compared with other GVHD recipients, donor T cells from gut but not spleen tissues of Non-GVHD recipients given ODC1-deficient T cells and transient AMXT-1501 treatment showed enhanced ferroptosis with 1) lower expression of anti-ferroptosis FTH1 and GPX4 genes and proteins as well as higher expression of pro-ferroptosis HMOX2 gene and protein, and additional higher expression of anti-apoptosis BCL2; 2) higher lipid peroxidation and mitochondrial superoxide, with increased levels of BODIPY C11 and MitoSOX, respectively; 3) reduced selenoamino acid metabolism as well as cholesterol, heme, and BH4 biosynthesis, which normally restrain lipid peroxidation and ferroptosis.
Our previous report showed that differential expression levels of PD-L1 in GVHD target gut and lymphoid spleen tissues contributed to separation of GVL activity from GVHD mediated by Stat3-/- T cells in a tissue PD-L1-dependent manner (PMID: 37526084). We currently observed that dual polyamine blockade led to preferential depletion of PD-1hi proinflammatory donor T-cell clones expressing high levels of IFN-γ, TNF-α, and GM-CSF but preserving anti-inflammatory T clones expressing high levels of IL-10 and FoxP3 in the gut but not spleen tissues. Consistently, dual polyamine blockades did not augment ferroptosis of donor T cells in the gut tissues or prevention of acute GVHD in PD-L1-/- recipients. In addition, combined inhibition of exogenous polyamine uptake with AMXT-1501 and endogenous polyamine synthesis with DFMO suppressed ex vivo murine and human alloreactive T cell proliferation, and the suppression was reversed by anti-PD-L1 mAb or ferroptosis inhibitor ferrostatin-1. Taken together, the results demonstrate that blockade of polyamine signaling augments ferroptosis of pathogenic T cells in the GVHD target tissues but not in the lymphoid tissues in a PD-L1/PD-1-dependent manner, and that simultaneous targeting exogenous and endogenous polyamines in the donor T cells early after HCT may represent an effective approach for preventing GVHD while preserving GVL effect (Grant support: R01HL162847 to Zeng).